Immune mechanisms of Concanavalin a model of autoimmune hepatitis

World Journal of Gastroenterology

Volumn 18, Issue 2, 2012, Pages 119-125

  Wang, Hai Xia ^a   Liu, Man ^b   Weng, Shun Yan ^b   Li, Jing Jing ^b   Xie, Chao ^b   He, Hong Lin ^b   Guan, Wen ^b   Yuan, Yun Sheng ^b   Gao, Jin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b ANHUI SCIENCE AND TECHNOLOGY UNIVERSITY   (China)

Author keywords

Animal models; Autoimmune hepatitis; Concanavalin A

Indexed keywords

APOLIPOPROTEIN A2; CONCANAVALIN A; GAMMA INTERFERON; HISTONE ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; OSTEOPONTIN; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE HEPATITIS; CYTOKINE RELEASE; DRUG INDUCED DISEASE; EVOLUTION; IMMUNE SYSTEM; LIVER TOXICITY; NONHUMAN; REVIEW;

EID: 84862943893     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v18.i2.119     Document Type: Review

References (66)

1. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology 2006; 43: S132-S144
2. Primo J, Maroto N, Martínez M, Antón MD, Zaragoza A, Giner R, Devesa F, Merino C, del Olmo JA. Incidence of adult form of autoimmune hepatitis in Valencia (Spain). Acta Gastroenterol Belg 2009; 72: 402-406
3. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960-967
4. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006; 43: 532-538
5. Al-Chalabi T, Underhill JA, Portmann BC, McFarlane IG, Heneghan MA. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol 2008; 48: 140-147
6. Häyry P, Gannedahl G. [Transplantation. Immunosuppression]. Nord Med 1994; 109: 191-193
7. Yang L, Liu YF, Liu SR, Wu G, Zhang JL, Meng YM, Shong SW, Li GC. Prevention and treatment of rejection after simultaneous pancreas-kidney transplantation. Chin Med Sci J 2005; 20: 210-213
8. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002; 35: 7-13
9. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002; 35: 890-897
10. van Mourik ID, Kelly DA. Immunosuppressive drugs in paediatric liver transplantation. Paediatr Drugs 2001; 3: 43-60
11. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, Taheri H, Kamalian N, Sotoudeh M. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001; 46: 1321-1327
12. Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol 2009; 51: 161-167
13. Teufel A, Weinmann A, Kahaly GJ, Centner C, Piendl A, Wörns M, Lohse AW, Galle PR, Kanzler S. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol 2010; 44: 208-213
14. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994; 8: 585-590
15. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36: 479-497
16. Czaja AJ. Animal models of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol 2010; 4: 429-443
17. Buschenfelde KH, Kossling FK, Miescher PA. Experimental chronic active hepatitis in rabbits following immunization with human liver proteins. Clin Exp Immunol 1972; 11: 99-108
18. Mihas AA, Subramony C, Achord JL. Experimental autoimmune hepatitis in mice following immunization with syngeneic liver proteins. J Med 1995; 26: 309-322
19. Lohse AW, Manns M, Dienes HP, Meyer zum Büschenfelde KH, Cohen IR. Experimental autoimmune hepatitis: disease induction, time course and T-cell reactivity. Hepatology 1990; 11: 24-30
20. Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 1992; 90: 196-203
21. Kim WH, Hong F, Radaeva S, Jaruga B, Fan S, Gao B. STAT1 plays an essential role in LPS/D-galactosamine-induced liver apoptosis and injury. Am J Physiol Gastrointest Liver Physiol 2003; 285: G761-G768
22. Jirillo E, Caccavo D, Magrone T, Piccigallo E, Amati L, Lembo A, Kalis C, Gumenscheimer M. The role of the liver in the response to LPS: experimental and clinical findings. J Endotoxin Res 2002; 8: 319-327
23. El Hefnawi MM, El Behaidy WH, Youssif AA, Ghalwash AZ, El Housseiny LA, Zada S. Natural genetic engineering of hepatitis C virus NS5A for immune system counterattack. Ann N Y Acad Sci 2009; 1178: 173-185
24. Pearson T, Greiner DL, Shultz LD. Creation of "humanized" mice to study human immunity. Curr Protoc Immunol 2008; Chapter 15: Unit 15.21
25. Guan Q, Ma Y, Hillman CL, Ma A, Zhou G, Qing G, Peng Z. Development of recombinant vaccines against IL-12/IL-23 p40 and in vivo evaluation of their effects in the downregulation of intestinal inflammation in murine colitis. Vaccine 2009; 27: 7096-7104
26. Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis. Hepatology 2010; 53: 536-547
27. Christen U, Holdener M, Hintermann E. Cytochrome P450 2D6 as a model antigen. Dig Dis 2010; 28: 80-85
28. Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. Hepatology 2004; 39: 1066-1074
29. Sass G, Heinlein S, Agli A, Bang R, Schümann J, Tiegs G. Cytokine expression in three mouse models of experimental hepatitis. Cytokine 2002; 19: 115-120
30. Tsui TY, Obed A, Siu YT, Yet SF, Prantl L, Schlitt HJ, Fan ST. Carbon monoxide inhalation rescues mice from fulminant hepatitis through improving hepatic energy metabolism. Shock 2007; 27: 165-171
31. Bertoletti A, Maini MK. Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr Opin Microbiol 2000; 3: 387-392
32. Hunter AL, Holscher MA, Neal RA. Thioacetamide-induced hepatic necrosis. I. Involvement of the mixed-function oxidase enzyme system. J Pharmacol Exp Ther 1977; 200: 439-448
33. Low TY, Leow CK, Salto-Tellez M, Chung MC. A proteomic analysis of thioacetamide-induced hepatotoxicity and cirrhosis in rat livers. Proteomics 2004; 4: 3960-3974
34. Thiele GM, Duryee MJ, Willis MS, Tuma DJ, Radio SJ, Hunter CD, Schaffert CS, Klassen LW. Autoimmune hepatitis induced by syngeneic liver cytosolic proteins biotransformed by alcohol metabolites. Alcohol Clin Exp Res 2010; 34: 2126-2136
35. Soares PA, Nascimento CO, Porto TS, Correia MT, Porto AL, Carneiro-da-Cunha MG. Purification of a lectin from Canavalia ensiformis using PEG-citrate aqueous two-phase system. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 457-460
36. Kanellopoulos PN, Pavlou K, Perrakis A, Agianian B, Vorgias CE, Mavrommatis C, Soufi M, Tucker PA, Hamodrakas SJ. The crystal structure of the complexes of concanavalin A with 4'-nitrophenyl-alpha-D-mannopyranoside and 4'-nitrophenyl-alpha-D-glucopyranoside. J Struct Biol 1996; 116: 345-355
37. Sato K, Imoto Y, Sugama J, Seki S, Inoue H, Odagiri T, Anzai J. Sugar-sensitive thin films composed of concanavalin A and glycogen. Anal Sci 2004; 20: 1247-1248
38. Fayad R, Sennello JA, Kim SH, Pini M, Dinarello CA, Fantuzzi G. Induction of thymocyte apoptosis by systemic administration of concanavalin A in mice: role of TNF-alpha, IFN-gamma and glucocorticoids. Eur J Immunol 2005; 35: 2304-2312
39. Carambia A, Herkel J. CD4 T cells in hepatic immune tolerance. J Autoimmun 2010; 34: 23-28
40. Zhang X, Wei HX, Rui S, Wei H, Tian Z. Opposite effects of high and low doses of interleukin-2 on T cell-mediated hepatitis in mice (interleukin-2 on hepatitis). Hepatol Int 2010; 4: 641-648
41. Varthaman A, Khallou-Laschet J, Clement M, Fornasa G, Kim HJ, Gaston AT, Dussiot M, Caligiuri G, Herbelin A, Kaveri S, Cantor H, Nicoletti A. Control of T cell reactivation by regulatory Qa-1-restricted CD8 T cells. J Immunol 2010; 184: 6585-6591
42. Zheng ZY, Weng SY, Yu Y. Signal molecule-mediated hepatic cell communication during liver regeneration. World J Gastroenterol 2009; 15: 5776-5783
43. van der Meer W, van Gelder W, de Keijzer R, Willems H. The divergent morphological classification of variant lymphocytes in blood smears. J Clin Pathol 2007; 60: 838-839
44. Shi X, Zhang P, Sempowski GD, Shellito JE. Thymopoietic and bone marrow response to murine Pneumocystis pneumonia. Infect Immun 2011; 79: 2031-2042
45. de Winther MP, Heeringa P. Bone marrow transplantations to study gene function in hematopoietic cells. Methods Mol Biol 2011; 693: 309-320
46. Peaudecerf L, dos Santos PR, Boudil A, Ezine S, Pardigon N, Rocha B. The role of the gut as a primary lymphoid organ: CD8αα intraepithelial T lymphocytes in euthymic mice derive from very immature CD44+ thymocyte precursors. Mucosal Immunol 2011; 4: 93-101
47. Tadmor T, Zhang Y, Cho HM, Podack ER, Rosenblatt JD. The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model. Cancer Immunol Immunother 2011; 60: 609-619
48. Repellin CE, Tsimbouri PM, Philbey AW, Wilson JB. Lymphoid hyperplasia and lymphoma in transgenic mice expressing the small non-coding RNA, EBER1 of Epstein-Barr virus. PLoS One 2010; 5: e9092
49. Final Report on Carcinogens Background Document for Formaldehyde. Rep Carcinog Backgr Doc 2010: i-512
50. Kage M. Pathology of autoimmune liver diseases in children. Hepatol Res 2007; 37 Suppl 3: S502-S508
51. Schümann J, Wolf D, Pahl A, Brune K, Papadopoulos T, van Rooijen N, Tiegs G. Importance of Kupffer cells for T-cell-dependent liver injury in mice. Am J Pathol 2000; 157: 1671-1683
52. Knolle PA, Gerken G, Loser E, Dienes HP, Gantner F, Tiegs G, Meyer zum Buschenfelde KH, Lohse AW. Role of sinusoidal endothelial cells of the liver in concanavalin A-induced hepatic injury in mice. Hepatology 1996; 24: 824-829
53. Wang J, Leclercq I, Brymora JM, Xu N, Ramezani-Moghadam M, London RM, Brigstock D, George J. Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology 2009; 137: 713-723
54. Gove ME, Rhodes DH, Pini M, van Baal JW, Sennello JA, Fayad R, Cabay RJ, Myers MG, Fantuzzi G. Role of leptin receptor-induced STAT3 signaling in modulation of intestinal and hepatic inflammation in mice. J Leukoc Biol 2009; 85: 491-496
55. Takahashi K, Murakami M, Kikuchi H, Oshima Y, Kubohara Y. Derivatives of Dictyostelium differentiation-inducing factors promote mitogen-activated IL-2 production via AP-1 in Jurkat cells. Life Sci 2011; 88: 480-485
56. Miller ML, Sun Y, Fu YX. Cutting edge: B and T lymphocyte attenuator signaling on NKT cells inhibits cytokine release and tissue injury in early immune responses. J Immunol 2009; 183: 32-36
57. Küsters S, Gantner F, Künstle G, Tiegs G. Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology 1996; 111: 462-471
58. Di Marco R, Xiang M, Zaccone P, Leonardi C, Franco S, Meroni P, Nicoletti F. Concanavalin A-induced hepatitis in mice is prevented by interleukin (IL)-10 and exacerbated by endogenous IL-10 deficiency. Autoimmunity 1999; 31: 75-83
59. Kato M, Ikeda N, Matsushita E, Kaneko S, Kobayashi K. Involvement of IL-10, an anti-inflammatory cytokine in murine liver injury induced by Concanavalin A. Hepatol Res 2001; 20: 232-243
60. Louis H, Le Moine A, Quertinmont E, Peny MO, Geerts A, Goldman M, Le Moine O, Devière J. Repeated concanavalin A challenge in mice induces an interleukin 10-producing phenotype and liver fibrosis. Hepatology 2000; 31: 381-390
61. Louis H, Van Laethem JL, Wu W, Quertinmont E, Degraef C, Van den Berg K, Demols A, Goldman M, Le Moine O, Geerts A, Devière J. Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice. Hepatology 1998; 28: 1607-1615
62. Tsukamoto H. Is interleukin-10 antifibrogenic in chronic liver injury? Hepatology 1998; 28: 1707-1709
63. Fan K, Zhang B, Yang H, Wang H, Tan M, Hou S, Qian W, Li B, Wang H, Dai J, Guo Y. A humanized anti-osteopontin antibody protects from Concanavalin A induced-liver injury in mice. Eur J Pharmacol 2011; 657: 144-151
64. Nakano T, Goto S, Lai CY, Hsu LW, Takaoka Y, Kawamoto S, Chiang KC, Shimada Y, Ohmori N, Goto T, Sato S, Ono K, Cheng YF, Chen CL. Immunological aspects and therapeutic significance of an autoantibody against histone H1 in a rat model of concanavalin A-induced hepatitis. Immunology 2010; 129: 547-555
65. Yamashita J, Iwamura C, Sasaki T, Mitsumori K, Ohshima K, Hada K, Hara N, Takahashi M, Kaneshiro Y, Tanaka H, Kaneko K, Nakayama T. Apolipoprotein A-II suppressed concanavalin A-induced hepatitis via the inhibition of CD4 T cell function. J Immunol 2011; 186: 3410-3420
66. Zhang H, Gong Q, Li JH, Kong XL, Tian L, Duan LH, Tong J, Song FF, Fang M, Zheng F, Xiong P, Tan Z, Gong FL. CpG ODN pretreatment attenuates concanavalin A-induced hepatitis in mice. Int Immunopharmacol 2010; 10: 79-85